A@s was a substudy of A@ , a prospective trial of @ ART-naive participants randomized to blinded abacavir-lamivudine ( ABC/@TC ) or tenofovir DF-emtricitabine ( TDF/FTC ) with open-label efavirenz ( EFV ) or atazanavir-ritonavir ( ATV/r ) .